Publications and communications of Jean-Yves Reginster

Fuggle, N. R., Beaudart, C., Bruyère, O., Abrahamsen, B., Al-Daghri, N., Burlet, N., Chandran, M., Rosa, M. M., Cortet, B., Demonceau, C., Dere, W., Halbout, P., Hiligsmann, M., Kanis, J. A., Kaufman, J.-M., Kurth, A., Lamy, O., Laslop, A., Maggi, S., ... Harvey, N. C. (14 March 2024). Evidence-Based Guideline for the management of osteoporosis in men. Nature Reviews Rheumatology, 20 (4), 241-251. doi:10.1038/s41584-024-01094-9

Sanchez-Rodriguez, D., Bruyère, O., Surquin, M., Reginster, J.-Y., & Beaudart, C. (05 March 2024). Towards a core outcome set (COS) for intrinsic capacity (IC) intervention studies in adults in midlife and beyond: a scoping review to identify frequently used outcomes and measurement tools. Aging Clinical and Experimental Research, 36 (1), 54. doi:10.1007/s40520-023-02681-8

Beaudart, C., Sharma, M., Clark, P., Fujiwara, S., Adachi, J. D., Messina, O. D., Morin, S. N., Kohlmeier, L. A., Sangan, C. B., Nogues, X., Cruz-Priego, G. A., Cavallo, A., Cooper, F., Grier, J., Leckie, C., Montiel-Ojeda, D., Papaioannou, A., Raskin, N., Yurquina, L., ... Hiligsmann, M. (March 2024). Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. Osteoporosis International, 35 (3), 451-468. doi:10.1007/s00198-023-06955-9

Kirk, B., Cawthon, P. M., Arai, H., Ávila-Funes, J. A., Barazzoni, R., Bhasin, S., Binder, E. F., Bruyère, O., Cederholm, T., Chen, L.-K., Cooper, C., Duque, G., Fielding, R., Guralnik, J., Kiel, D. P., Landi, F., Reginster, J.-Y., Sayer, A. A., Visser, M., ... Global Leadership Initiative in Sarcopenia (GLIS) group. (01 March 2024). The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age and Ageing, 53 (3). doi:10.1093/ageing/afae052

Kim, A., Hong, J. H., Shin, W., Yoo, H., Jung, J.-G., Reginster, J.-Y., Kim, S., Bae, Y., Suh, J., Kim, S., Lee, E., & Silverman, S. (2024). A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert Opinion on Biological Therapy, 1 - 9. doi:10.1080/14712598.2024.2316846

Herrero-Beaumont, G., Castro-Dominguez, F., Migliore, A., Naredo, E., Largo, R., & Reginster, J.-Y. (20 February 2024). Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clinical and Experimental Research, 36 (1), 45. doi:10.1007/s40520-024-02714-w

Hiligsmann, M., Silverman, S. L., Singer, A. J., Pearman, L., Wang, Y., Caminis, J., & Reginster, J.-Y. (30 January 2024). Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clinical and Experimental Research, 36 (1), 14. doi:10.1007/s40520-023-02682-7

Vendrami, C., Shevroja, E., Gonzalez Rodriguez, E., Gatineau, G., Elmers, J., Reginster, J.-Y., Harvey, N. C., Lamy, O., & Hans, D. (2024). Muscle parameters in fragility fracture risk prediction in older adults: A scoping review. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13418

Beaudart, C., Tilquin, N., Abramowicz, P., Baptista, F., Peng, D. J., de Souza Orlandi, F., Drey, M., Dzhus, M., Fábrega-Cuadros, R., Fernandez-Garrido, J., Laurindo, L. F., Gasparik, A.-I., Geerinck, A., Emin, G., Iacob, S., Kilaitė, J., Kumar, P., Lee, S.-C., Lou, V. W. Q., ... Bruyère, O. (15 December 2023). Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data. Maturitas, 180, 107902. doi:10.1016/j.maturitas.2023.107902

Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (06 November 2023). Quality of Life and Health Determinants of Informal Caregivers Aged 65 Years and Over. Epidemiologia (Basel, Switzerland), 4 (4), 464 - 482. doi:10.3390/epidemiologia4040039

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Assessment of risk factors associated with long-term mortality in nursing homes: result from the SENIOR cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02579-5

Honvo, G., Sabico, S., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Mikton, C., Diaz, T., Cooper, C., & Reginster, J.-Y. (28 October 2023). Measures of attributes of locomotor capacity in older people: a systematic literature review following the COSMIN methodology. Age and Ageing, 52 (Supplement_4), 44 - iv66. doi:10.1093/ageing/afad139

Veronese, N., Soysal, P., Demurtas, J., Solmi, M., Bruyère, O., Christodoulou, N., Ramalho, R., Fusar-Poli, P., Lappas, A. S., Pinto, D., Frederiksen, K. S., Corbi, G. M., Karpenko, O., Georges, J., Durães, J., Schlögl, M., Yilmaz, O., Sieber, C., Shenkin, S. D., ... endorsed by the European Academy of Neurology. (October 2023). Physical activity and exercise for the prevention and management of mild cognitive impairment and dementia: a collaborative international guideline. European Geriatric Medicine, 14 (5), 925 - 952. doi:10.1007/s41999-023-00858-y

Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Fuggle, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (September 2023). Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (9), 1789 - 1806. doi:10.1007/s40520-023-02478-9

Moon, R. J., Reginster, J.-Y., Al-Daghri, N., Thiyagarajan, J. A., Beaudart, C., Bruyère, O., Burlet, N., Chandran, M., da Silva, M. C., Conaghan, P. G., Dere, W. H., Diez-Perez, A., Hadji, P., Halbout, P., Hiligsmann, M., Kanis, J. A., McCloskey, E. V., Ormarsdottir, S., Prieto-Alhambra, D., ... Harvey, N. C. (August 2023). Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 34 (8), 1283 - 1299. doi:10.1007/s00198-023-06827-2

Cooper, C., Dawson-Hughes, B., Halbout, P., Harvey, N., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., & International Osteoporosis Foundation. (July 2023). In Memoriam : Lorie Fitzpatrick MD - 1954-2023. Osteoporosis International, 34 (7), 1281 - 1282. doi:10.1007/s00198-023-06767-x

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (July 2023). Investigation of the relationships between frailty, nutritional status and muscle strength and the incidence and severity of Covid-19 among the residents of nursing homes. Results from the SENIOR cohort. Maturitas, 177, 107800. doi:10.1016/j.maturitas.2023.107800

Pegreffi, F., Reginster, J.-Y., Bruyère, O., & Veronese, N. (June 2023). Comment on: The Effect of Intra-articular Hyaluronic Acid Injections and Payer Coverage on Total Knee Arthroplasty Procedures: Evidence From Large US Claims Database. Arthroplasty Today, 21, 101128. doi:10.1016/j.artd.2023.101128

Messina, O. D., Vidal, M., Adami, G., Vidal, L. F., Clark, P., Torres, J. A. M., Lems, W., Zerbini, C., Arguissain, C., Reginster, J.-Y., & Lane, N. E. (2023). Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02432-9

Beaudart, C., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., Bautmans, I., Bauer, J., Burlet, N., Cesari, M., Cherubini, A., Cooper, C., Cruz-Jentoft, A. J., Dawson-Hughes, B., Fielding, R. A., Harvey, N. C., Landi, F., Laslop, A., Maggi, S., Montero-Errasquin, B., Concepción, P. Y. M., Rolland, Y., ... Bruyère, O. (23 May 2023). Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties. Aging Clinical and Experimental Research, 35, 1581-1593. doi:10.1007/s40520-023-02438-3

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (06 May 2023). Predictors of 8-year survival in nursing homes : Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain.

Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Sarcopenia and health-related quality of life: A systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13243

Hiligsmann, M., Silverman, S. S., Singer, A. J., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2023). Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. PharmacoEconomics. doi:10.1007/s40273-023-01270-x

Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 363 - 391. doi:10.1007/s40273-022-01239-2

Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 393. doi:10.1007/s40273-023-01255-w

Prokopidis, K., Giannos, P., Reginster, J.-Y., Bruyère, O., Petrovic, M., Cherubini, A., Triantafyllidis, K. K., Kechagias, K. S., Dionyssiotis, Y., Cesari, M., Ibrahim, K., Scott, D., Barbagallo, M., Veronese, N., & Special interest group in Systematic Reviews and Meta-analyses and the Task Force on Pharmaceutical Strategy of the European Geriatric Medicine Society (EuGMS). (April 2023). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14 (2), 671 - 683. doi:10.1002/jcsm.13190

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (08 March 2023). Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand. Medicines (Basel, Switzerland), 10 (3), 23. doi:10.3390/medicines10030023

Ladang, A., Beaudart, C., Reginster, J.-Y., Al-Daghri, N., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Laslop, A., Maggi, S., Mobasheri, A., Ormarsdottir, S., Radermecker, R., Visser, M., Yerro, M. C. P., ... Cavalier, E. (12 January 2023). Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcified Tissue International, online. doi:10.1007/s00223-022-01054-z

Westbury, L. D., Beaudart, C., Bruyère, O., Cauley, J. A., Cawthon, P., Cruz-Jentoft, A. J., Curtis, E. M., Ensrud, K., Fielding, R., Johansson, H., Kanis, J. A., Karlsson, M. K., Lane, N. E., Lengele, L., Lorentzon, M., McCloskey, E., Mellström, D., Newman, A. B., Ohlsson, C., ... International Musculoskeletal Ageing Network. (05 January 2023). Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts. Journal of Cachexia, Sarcopenia and Muscle, online. doi:10.1002/jcsm.13160

Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (03 January 2023). Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, online. doi:10.1007/s40520-022-02319-1

Beaudart, C., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Measure of health-related quality of life in interventional studies aiming at the management of sarcopenia: results from a systematic literature review. Aging Clinical and Experimental Research, 35 (suppl 1), 190.

Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Health-related quality of life in sarcopenia: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 58-59.

Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (2023). Efficacy of osteoporosis treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 249.

Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Screening for malnutrition by the MNA-SF, diagnosis by the Global Leadership Initiative on Malnutrition (GLIM) criteria, or both? Predictive capacity for mortality in a 9-year follow-up in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 335.

Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Intrinsic capacity using the MNA-SF and the Global Leadership Initiative of Malnutrition (GLIM) criteria in the nutritional domain and mortality-risk: A 9-year follow-up in the SarcoPhAge cohortr. Aging Clinical and Experimental Research, 35 (suppl 1), 334-S335.

Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (2023). Health determinants of informal caregivers aged 65 years and over. Aging Clinical and Experimental Research, 35 (suppl 1), 288.

Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). L’activité physique en maison de repos : contributions de la cohorte SENIOR. Revue Médicale de Liège.

Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Etude de la survenue des événements de santé indésirables en maison de repos : apports de la cohorte Liégeoise SENIOR. Revue Médicale de Liège, 78, 715-718.

Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2023). Development and validation of new exercises to promote physical activity in nursing home settings, through qualitative method. Aging Clinical and Experimental Research, 35 (suppl 1), 51.

Demonceau, C., Beaudart, C., Reginster, J.-Y., Veronese, N., & Bruyère, O. (2023). The interconnection between Covid-19, sarcopenia and lifestyle. Maturitas, 169, 56-57. doi:10.1016/j.maturitas.2022.09.009

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Predictors of 8-year survival in nursing homes: results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 60.

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of COVID-19 in nursing home. Results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 306.

Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of Covid-19 in nursing home. Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain.

Tenti, S., Bruyère, O., Cheleschi, S., Reginster, J.-Y., Veronese, N., & Fioravanti, A. (2023). An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 15, 1759720X231158618. doi:10.1177/1759720X231158618

Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2023). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research, 35 (suppl 1), 271.

Zhao, X.-X., Xie, W.-Q., Xiao, W.-F., Li, H.-Z., Naranmandakh, S., Bruyere, O., Reginster, J.-Y., & Li, Y.-S. (2023). Perlecan: Roles in osteoarthritis and potential treating target. Life Sciences, 312. doi:10.1016/j.lfs.2022.121190

Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (07 November 2022). Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clinical and Experimental Research, 34, 3155-3157. doi:10.1007/s40520-022-02216-7

Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Smith, L., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2022). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research. doi:10.1007/s40520-022-02289-4

Chevalley, T., Brandi, M. L., Cashman, K. D., Cavalier, E., Harvey, N. C., Maggi, S., Cooper, C., Al-Daghri, N., Bock, O., Bruyère, O., Rosa, M. M., Cortet, B., Cruz-Jentoft, A. J., Cherubini, A., Dawson-Hughes, B., Fielding, R., Fuggle, N., Halbout, P., Kanis, J. A., ... Rizzoli, R. (November 2022). Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clinical and Experimental Research, 34 (11), 2603 - 2623. doi:10.1007/s40520-022-02279-6

Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (November 2022). Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, 34 (11), 2625 - 2634. doi:10.1007/s40520-022-02272-z

Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (2022). The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporosis International. doi:10.1007/s00198-022-06567-9

Veronese, N., & Reginster, J.-Y. (18 October 2022). Authors' Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (14), 1513-1514. doi:10.1007/s40265-022-01789-x

Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (16 September 2022). Development and Validation of New Exercises to Promote Physical Activity in Nursing Home Settings. Geriatrics, 7 (5), 100. doi:10.3390/geriatrics7050100

Veronese, N., Cooper, C., Bruyère, O., Al-Daghri, N., Branco, J., Cavalier, E., Cheleschi, S., da Silva Rosa, M. C., Conaghan, P. G., Dennison, E. M., de Wit, M., Fioravanti, A., Fuggle, N. R., Haugen, I. K., Herrero-Beaumont, G., Honvo, G., Laslop, A., Matijevic, R., Migliore, A., ... Reginster, J.-Y. (16 September 2022). Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (13), 1347-1355. doi:10.1007/s40265-022-01773-5

Veronese, N., Bolzetta, F., Cacco, C., Cester, A., Smith, L., Demurtas, J., Cooper, C., Rizzoli, R., Caruso, M. G., Notarnicola, M., Reginster, J.-Y., Maggi, S., Barbagallo, M., Trott, M., & Dominguez, L. J. (13 August 2022). Dietary acrylamide and incident osteoporotic fractures: an 8-year prospective cohort study. Aging Clinical and Experimental Research, 34 (10), 2441-2448. doi:10.1007/s40520-022-02214-9

BRUYERE, O., Reginster, J.-Y., & Honvo, G. (August 2022). Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial. Rheumatology and Therapy, 9 (4), 1119-1128. doi:10.1007/s40744-022-00466-5

BRUYERE, O., Reginster, J.-Y., & Beaudart, C. (July 2022). Lifestyle approaches to prevent and retard sarcopenia: A narrative review. Maturitas, 161, 44-48. doi:10.1016/j.maturitas.2022.02.004

Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2022). Ostéosarcopénie : quand les deux ne font qu'un. Medi-Sphere, (705), 14-16.

Hiligsmann, M., Li, N., Cooper, C., Reginster, J.-Y., Silverman, S., Carswell, C., & Husereau, D. (12 April 2022). Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. Osteoporosis International, 33 (8), 1641-1642. doi:10.1007/s00198-022-06400-3

Arden, N., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2022). How can we explain the differences between the OARSI and ESCEO Guidelines for the management of knee osteoarthritis? Osteoporosis International, 32 (Suppl 1), 57-58.

Bahat, G., Muge Catikkas, N., Yavuz, D. G., Borman, P., Guzel, R., Esra Bozkurt, M., & Reginster, J.-Y. (2022). The current situation in the approach to osteoporosis in older adults in Turkey: aeas in need of improvement with a model for other populations. Aging Clinical and Experimental Research, 34 (S1), 96.

Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient’s preferences for lifestyle changes in osteoporotic fracture prevention: a cross-european discrete-choice experiment. Osteoporosis International, 32 (supp1), 89 and 46-47.

Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 33, 1335-1346. doi:10.1007/s00198-022-06310-4

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2022). Health technology assessment of different glucosamine formultaions and preparations currently marketed in Thailand: impact of their clinical effect and selling price. Aging Clinical and Experimental Research, 34 (S1), 285.

Bruyère, O., Reginster, J.-Y., & Honvo, G. (2022). Health economics evaluation of a high and low molecular weight hyaluronic acid formulation in patients with knee osteoarthritis. Analysis from a randomized clinical trial. Aging Clinical and Experimental Research, 34 (S1), 50.

Cheleschi, S., Tenti, S., Seccafico, I., Mondanelli, N., Reginster, J.-Y., & Fioravanti, A. (2022). MicroRNA as possible mediators of celecoxib and glucosamine sulfate-induced effects on apoptosis and oxidative stress: an in vitro study on human osteoarthritic chondrocytes. Aging Clinical and Experimental Research, 34 (S1), 239-240.

Geerinck, A., Beaudart, C., Reginster, J.-Y., Wojszel, Z. B., De Souza Orlandi, F., Bahat, G., Erdogan, T., Montero-Errasquin, B., Alekna, V., & Bruyère, O. (2022). Measurement properties of the Short Form Sarcopenia Quality of Life (SF-SARQOL) Questionnaire in an international dataset. Osteoporosis International, 32 (Suppl 1), 249.

Geerinck, A., Locquet, M., Hiligsmann, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2022). Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study. European Geriatric Medicine, 13 (2), 483-91. doi:10.1007/s41999-021-00563-8

Hiligsmann, M., Silverman, S., Singer, A., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2022). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate in US men at imminent risk of fracture. Journal of Managed Care and Specialty Pharmacy, 28, 105.

Honvo, G., Reginster, J.-Y., Mobasheri, A., Lengele, L., Avouac, B., Rizzoli, R., & Bruyère, O. (2022). Post-marketing safety surveillance of anti-osteoarthritis drugs: a protocol for a systematic review of published literature. Osteoporosis International, 32 (Suppl 1), 242-243.

Honvo, G., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Cooper, C., & Reginster, J.-Y. (2022). Measurement tools for attributes of locomotor capacity in older people: protocol for a systematic review of available tools and evidence-based recommendations. Aging Clinical and Experimental Research, 34 (S1), 450.

Kanis, J. A., Harvey, N. C., McCloskey, E., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., Minski, O., ... Reginster, J.-Y. (2022). Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 33 (Suppl 1), 24.

Ladang, A., Kovacs, S., Lengele, L., Locquet, M., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament light chain concentration in an aging population. Aging Clinical and Experimental Research, 34 (2), 331-339. doi:10.1007/s40520-021-02054-z

LADANG, A., KOVACS, S., Lengele, L., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in sarcopenic patients: results of the sarcophage study. Osteoporosis International, 32 (Suppl 1), 53.

Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., KAUX, J.-F., Gillain, S., Reginster, J.-Y., & Bruyère, O. (January 2022). Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clinical and Experimental Research, 34 (1), 223-234. doi:10.1007/s40520-021-01991-z

Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., Kaux, J.-F., Gillain, S., Shadouh, C., Reginster, J.-Y., & Bruyère, O. (2022). Relationships between malnutrition, sarcopenia, and frailty and the incidence of Covid-19 in older adults: data from the sarcophage cohort. Osteoporosis International, 32 (Suppl 1), 50.

Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2022). An assessment of the Toulouse Saint Louis University mini falls assessment tool to predict incident falls among older adults residing in nursing homes: a 6-month prospective study. Osteoporosis International, 32 (Suppl 1), 230.

Locquet, M., Sanchez Rodriguez, M. D. C., Bruyère, O., Geerinck, A., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2022). Intrinsic Capacity Defined Using Four Domains and Mortality Risk: A 5-Year Follow-Up of the SarcoPhAge Cohort. The journal of nutrition, health & aging, 26 (1), 23-29. doi:10.1007/s12603-021-1702-7

Messina O.D., Clarck, P. E. C., Mendez-Sanchez L.M.S., Peralta, M. L. P., Cerdas, S., Campusano, C., Visal Neira, L. F., Lasaretti Castro, M. L., Morales Torres, J., Harvey, N. C., Reginster, J.-Y., & Zerbini, C. F. (2022). Latin American consensus on the management of glucocorticoid induces osteoporosis : a preliminary communication. Osteoporosis International, 32 (supp 1), 288-289.

Reginster, J.-Y. (2022). Шановні читачі! Bolʹ, Sustavy, Pozvonočnik, 12 (1), 1. doi:10.22141/pjs.12.1.2022.321

Reginster, J.-Y. (2022). Multimodal pharmacological approach: from evidence-based to daily practice. Aging Clinical and Experimental Research, 34 (S1), 103.

Reginster, J.-Y. (2022). Management of hand osteoarthritis: how can the ACR guidelines be applied to an European population in a patient-centric approach. Aging Clinical and Experimental Research, 34 (S1), 55.

Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., BRUYERE, O., Reginster, J.-Y., & Fioravanti, A. (2022). Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study. Aging Clinical and Experimental Research, 34 (7), 1613-1625. doi:10.1007/s40520-022-02151-7

Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., Reginster, J.-Y., & Fioravanti, A. (2022). Erosive osteoarthritis of the hand: efficacy of prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments. Aging Clinical and Experimental Research, 34 (S1), 49-50.

Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Honvo, G., & Maggi, S. (2022). Glucosamine sulphate: an umbrella review of health outcomes. Osteoporosis International, 32 (Suppl 1), 43.

Veronese, N., Honvo, G., Amuthavalli Thiyagarajan, J., Rizzoli, R., Cooper, C., BRUYERE, O., Mikton, C., Sumi, Y., Diaz, T., Reginster, J.-Y., Banerjee, A., & members of the WHO Collaborating Center Working Group on Locomotor Capacity. (2022). Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 34 (3), 481-483. doi:10.1007/s40520-022-02080-5

Veronese, N., Smith, L., Zigoura, E., Barbagallo, M., Dominguez, L. J., Barone, A., Cella, A., Cooper, C., Rizzoli, R., Reginster, J.-Y., Maggi, S., & Pilotto, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative. Archives of Osteoporosis, 17 (1), 5. doi:10.1007/s11657-021-01015-3

Veronese, N., Smith, L., ZIGOURA, E., BARBAGALLO, M., DOMINGUEZ, M., COOPER, C., RIZZOLI, R., Reginster, J.-Y., MAGGI, S., & PILOTTO, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the osteoarthritis initiative. Osteoporosis International, 32 (supp1), 46.

Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Di Bella, G., Mandalà, C., Dominguez, L., Smith, L., & Maggi, S. (2022). Lower limb muscle strength and muscle mass are associated with incident symptomatic knee osteoarthritis: a longitudinal cohort study. Aging Clinical and Experimental Research, 34 (S1), 50.

Chevalley, T., Brandi, M., Cavalier, E., Harvey, N., Iolascon, G., Cooper, C., Hannouche, D., Kaux, J.-F., Kurth, A., Maggi, S., Maier, G., Papavasiliou, K., Al-Daghri, N., Sosa-Henriquez, M., Suhm, N., Tarantino, U., Reginster, J.-Y., & Rizzoli, R. (October 2021). How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? Osteoporosis International, 32 (10), 1921-1935. doi:10.1007/s00198-021-05957-9

Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, N. C., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (April 2021). Correction to: How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32 (4), 801. doi:10.1007/s00198-021-05905-7

Arden, N. K., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2021). Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology, 17, 59-66. doi:10.1038/s41584-020-00523-9

Bahat, G., Catikkas, N. M., KARAN, M. A., & Reginster, J.-Y. (2021). Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey. Archives of Osteoporosis, 16. doi:10.1007/s11657-021-00967-w

Bahat, G., Catikkas, N. M., Yavuz, D. G., Borman, P., Guzel, R., & Reginster, J.-Y. (2021). The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. Archives of Osteoporosis, 16 (1). doi:10.1007/s11657-021-01038-w

Beaudart, C., Bauer, J. M., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2021). Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). Aging Clinical and Experimental Research, 33, 1079-1083. doi:10.1007/s40520-021-01794-2

Beaudart, C., Bonnefoy, M., Gilbert, T., Paillaud, E., Raynaud-Simon, A., Guérin, O., Jeandel, C., Le Sourd, B., Haine, M., Ferry, M., Rolland, Y., Berrut, G., Reginster, J.-Y., & Bruyère, O. (2021). Quelle qualité de vie pour le patient sarcopénique ? Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 19 (3), 245-252. doi:10.1684/pnv.2021.0948

Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2021). Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. Current Aging Science, 14 (3), 242-248. doi:10.2174/1874609814666210415092845

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (2021). Using health-economic evidence to support policy-level decision-making in Singapore-sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32, 787-789. doi:10.1007/s00198-021-05876-9

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (January 2021). Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 32 (1), 133-144. doi:10.1007/s00198-020-05536-4

Cheleschi, S., Tenti, S., Giannotti, S., Veronese, N., Reginster, J.-Y., & Fioravanti, A. (2021). A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. International Journal of Molecular Sciences, 22, 8980. doi:10.3390/ijms22168980

Cooper, C., Halbout, P., Dawson-hughes, B., Harvey, N. C., Kanis, J. A., Reginster, J.-Y., & Rizzoli, R. (2021). In memory of Harry K. Genant. Osteoporosis International, 32, 607-608. doi:10.1007/s00198-021-05857-y

Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, C. N., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (2021). How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32, 611-617. doi:10.1007/s00198-020-05793-3

Geerinck, A., Beaudart, C., Reginster, J.-Y., Locquet, M., Monseur, C., GILLAIN, S., & Bruyère, O. (2021). Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF‑SarQoL. Quality of Life Research, 30 (8), 2349-2362. doi:10.1007/s11136-021-02823-3

Geerinck, A., Dawson-Hughes, B., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2021). Assessment of the performance of the SarQoL questionnaire in screening for sarcopenia in older people. Aging Clinical and Experimental Research, 33, 2149-2155. doi:10.1007/s40520-021-01913-z

Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2021). Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL(®) questionnaire. Journal of Cachexia, Sarcopenia and Muscle, 12 (2), 319-330. doi:10.1002/jcsm.12687

Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Letter to the Editor: Discriminative Power of the Sarcopenia Quality of Life (SarQoL®) Questionnaire with the EWGSOP2 Criteria [letter to the editor]. The Journal of frailty & aging, 10 (2), 193-194. doi:10.14283/jfa.2020.47

Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Discriminative power of the Sarcopenia Quality of Life (SarQoL) questionnaire with the EWGSOP2 criteria [letter to the editor]. Journal of Frailty and Aging, 10 (2), 193-194.

Grygorieva, N., Povoroznyuk, R., Matijevic, R., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2021). In memoriam: Vladyslav Povoroznyuk. Osteoporosis International, 32 (9), 1905-1906. doi:10.1007/s00198-021-06048-5

Hiligsmann, M., Maggi, S., Veronese, N., Sartori, L., & Reginster, J.-Y. (2021). Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 32, 595-606. doi:10.1007/s00198-020-05802-5

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 33 (6), 1507-1517. doi:10.1007/s40520-021-01880-5

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Impact of malnutrition status on muscle parameter changes over a 5-year follow-up of community-dwelling older adults from the SarcoPhage Cohort. Nutrients, 13 (2), 407. doi:10.3390/nu13020407

Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Loquet, M. (2021). Correction to: Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5‑year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-021-01901-3

Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., de Bot, R., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2021). An Updated Systematic Review of Cost‑Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics, 39, 181-209. doi:10.1007/s40273-020-00965-9

Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2021). An Assessment of the Toulouse Saint Louis University Mini Falls Assessment Tool to Predict Incident Falls among Older Adults Residing in Nursing Homes: A 6-Month Prospective Study. Journal of Nutrition, Health and Aging, 25 (7), 933-937. doi:10.1007/s12603-021-1651-1

Locquet, M., Bruyère, O., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2021). Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health, 193, 101-108. doi:10.1016/j.puhe.2021.01.017

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C., Chines, A., & Oates, M. K. (2021). Skeletal responses to romosozumab after 12 months of denosumab. Journal of Bone and Mineral Research Plus, 5 (7), 10512. doi:10.1002/jbm4.10512

Migliore, A., Blicharski, T., Plebanski, R., Zegota, Z., Gyula, G., Rannou, F., & Reginster, J.-Y. (2021). Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial. Rheumatology and Therapy, 8 (4), 1617-1636. doi:10.1007/s40744-021-00363-3

Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petit-Dop, F., Chapurlat, R., Reginster, J.-Y., Cooper, C., & Inskip, H. (January 2021). Determining individual trajectories of joint space loss: improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoarthritis and Cartilage, 29 (1), 59-67. doi:10.1016/j.joca.2020.09.009

Reginster, J.-Y., Beaudart, C., Al-Daghri, N., Avouac, B., Bauer, J., Bere, N., Bruyère, O., Cerreta, F., Cesari, M., Rosa, M. M., Cooper, C., Cruz Jentoft, A. J., Dennison, E., Geerinck, A., Gielen, E., Landi, F., Laslop, A., Maggi, S., Prieto Yerro, M. C., ... Fielding, R. A. (2021). Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 33, 3-17. doi:10.1007/s40520-020-01663-4

Reginster, J.-Y., & Veronese, N. (2021). Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clinical and Experimental Research, 33, 37-47. doi:10.1007/s40520-020-01643-8

Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J.-Y., Vellas, B., & Cruz-Jentoft, A. J. (2021). Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020. The Journal of frailty & aging, 10 (2), 168-175. doi:10.14283/jfa.2021.4

Sanchez Rodriguez, M. D. C., Locquet, M., Bruyère, O., Lengele, L., CAVALIER, E., Reginster, J.-Y., & Beaudart, C. (2021). Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. Clinical Nutrition, 40 (4), 2188-2199. doi:10.1016/j.clnu.2020.09.047

Slomian, J., Reginster, J.-Y., Emonts, P., & Bruyère, O. (2021). Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. BMC Pregnancy and Childbirth, 21 (1), 405. doi:10.1186/s12884-021-03858-7

Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N. M., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Dominguez, L. J., Smith, L., & Maggi, S. (2021). Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study. Frontiers in Endocrinology, 12. doi:10.3389/fendo.2021.804560

Yeap, S. S., Tanavalee, A., Perez, E. C., Tan, M. P., Reyes, B. H. M., Lee, J. K., Norhamdan, M. Y., Vista, E. S., Chan, W. S., Cong, S. B., Tam, P. T. T., Kaufman, J.-M., Reginster, J.-Y., Veronese, N., & Penserga, E. (2021). 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clinical and Experimental Research, 33, 1149-1156. doi:10.1007/s40520-021-01834-x

Zhang, Z., Huang, C., Cao, Y., Mu, R., Zhang, M. C., Xing, D., Fan, D., Ding, Y., Guo, J., Hou, Y., Jianhao, L., Veronese, N., Reginster, J.-Y., Bruyère, O., Cavalier, E., & Zhang, H. (2021). 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clinical and Experimental Research, 33 (8), 2141-2147. doi:10.1007/s40520-021-01906-y

Beaudart, C., Lengele, L., Leclercq, V., Geerinck, A., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (December 2020). Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta‑Analysis with a 6‑Month Time Horizon. Drugs, 80 (18), 1947-1959. doi:10.1007/s40265-020-01423-8

DEROISY, R., NEUPREZ, A., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., Reginster, J.-Y., & KAUX, J.-F. (December 2020). Identification, through a Fracture Liaison Service, of undiagnosed vertebral fractures in patients hospitalized for a prevalent hip fragility fracture. Osteoporosis International, 31 (S1), 200.

Honvo, G., Lengele, L., Charles, A., Reginster, J.-Y., & Bruyère, O. (December 2020). Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatology and Therapy, 7 (4), 703-740. doi:10.1007/s40744-020-00240-5

NEUPREZ, A., DEROISY, R., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., KAUX, J.-F., & Reginster, J.-Y. (December 2020). Secondary fracture prevention in hip fracture patients: 6-year impact of a Fracture Liaison Service. Osteoporosis International, 31 (S1), 199-200.

Buckinx, F., Lecocq, G., Bornheim, S., Van Beveren, J., VALCU, C.-A., DANIEL, C., Bruyère, O., Reginster, J.-Y., D'Hooghe, P., & Kaux, J.-F. (August 2020). French translation and validation of the Achilles Tendon Total Rupture Score "ATRS". Foot and Ankle Surgery, 26 (6), 662-668. doi:10.1016/j.fas.2019.08.010

Locquet, M., Willems, T., Specque, C., Beaudart, C., Bruyère, O., Van Beveren, J., Dardenne, N., Reginster, J.-Y., & Kaux, J.-F. (July 2020). Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. Disability and Rehabilitation, 42 (14), 2076-2082. doi:10.1080/09638288.2018.1544669

Fuggle, N. R., Cooper, C., Oreffo, R. O. C., Price, A. J., Kaux, J.-F., Maheu, E., Cutolo, M., Honvo, G., Conaghan, P. G., Berenbaum, F., Branco, J., Brandi, M. L., Cortet, B., Veronese, N., Kurth, A. A., Matijevic, R., Roth, R., Pelletier, J. P., Martel-Pelletier, J., ... Reginster, J.-Y. (April 2020). Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 32 (4), 547-560. doi:10.1007/s40520-020-01515-1

Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., Hustin, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (March 2020). Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical Rheumatology, 39 (3), 861-871. doi:10.1007/s10067-019-04811-y

ALLEPAERTS, S., Buckinx, F., Bruyère, O., Reginster, J.-Y., PAQUOT, N., & GILLAIN, S. (2020). Clinical impact of nutritional status and energy balance in elderly hospitalized patients. Journal of Nutrition, Health and Aging, 24 (10), 1073-79. doi:10.1007/s12603-020-1527-9

Beaudart, C., Bauer, J., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2020). A discrete-choice experiment to assess experts’ preferences for sarcopenia outcomes. Osteoporosis International, 31 (S1), 320.

Beaudart, C., Lengele, L., Geerinck, A., Leclercq, V., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (2020). Efficacy of symptomatic treatments for knee OA: a systematic review and network meta-analysis with a 6-month time-horizon. Osteoporosis International, 31 (S1), 56.

Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). The different diagnosis criteria of the EWGSOP2 definition and long-term clinical outcomes. Osteoporosis International, 31 (S1), 58.

Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). Performance of the “Yubi-wakka (finger-ring) test as self-screening method for sarcopenia using the SarcoPhAge, Belgian cohort study. Osteoporosis International, 31 (S1), 85 and 302.

Bruyère, O., Dardenne, N., Donneau, A.-F., & Reginster, J.-Y. (2020). Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. Advances in Therapy, 37 (11), 4641-4648. doi:10.1007/s12325-020-01484-x

Buckinx, F., Marchal, Q., Hurtrez, P., Bruyère, O., Reginster, J.-Y., & Mouton, A. (2020). The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: a randomized controlled trial. Osteoporosis International, 31 (S1), 261.

Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., Yong, E. L., & Hiligsmann, M. (2020). Cost-effectiveness of FRAX® based intervention tresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 31 (S1), 459.

Charles, A., Buckinx, F., Reginster, J.-Y., Mouton, A., & Bruyère, O. (2020). Motivational climate of group exercise sessions in nursing homes. Osteoporosis International, 31 (S1), 217-218.

Charles, A., Detilleux, J., Buckinx, F., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (2020). Physical performance trajectories and mortality among nursing-home residents: the results of the SENIOR Cohort. Osteoporosis International, 31 (S1), 57.

Charles, A., Girard, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Senior physical activity contests in nursing homes: a feasibility study. Osteoporosis International, 31 (S1), 217.

Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., & Hiligsmann, M. (2020). Interventions to improve adherence to anti-osteoporosis medications: an updted systematic review. Osteoporosis International, 31 (9), 1645-1669. doi:10.1007/s00198-020-05378-0

Dzhus, M., Dzhus, M., Masnyi, M., Kulyk, M., Mostbauer, H., Ivashkivsky, O., Boyko, Y., Cherchenko, K., Geerinck, A., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2020). Cross-sectional evaluation of the sarcopenia quality of life (Sarqol) questionnaire: Translation and validation of its psychometric properties. Annals of Geriatric Medicine and Research, 24 (2), 139-147. doi:10.4235/AGMR.20.0020

Fuggle, N. R., Cooper, C., Harvey, N. C., Al-Daghri, N., Brandi, M.-L., Bruyère, O., Cano, A., Dennison, E. M., Diez-Perez, A., Kaufman, J.-M., Palacios, S., Prieto-Alhambra, D., Rozenberg, S., Thomas, T., Tremollieres, F., Rizzoli, R., Kanis, J. A., & Reginster, J.-Y. (2020). Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 80 (15), 1537-52. doi:10.1007/s40265-020-01364-2

Fuggle, N. R., Kassim Javaid, M., Fujita, M., Halbout, P., Dawson-Hughes, B., Rizzoli, R., Reginster, J.-Y., Kanis, J., & Cooper, C. (2020). Fracture risk assessment and how to implement a Fracture Liaison Service. In Orthogeriatrics: The management of older patients with fragility fractures (Second Edition, pp. 241-256). Paolo Falaschi, David Marsh Eds. doi:10.1007/978-3-030-48126-1

Geerinck, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). Association between SARC-F and quality of life measured by SARQOL® questionnaire in older, community-dwelling subjects friom the SarcoPhAge cohort. Osteoporosis International, 31 (S1), 451.

Geerinck, A., Bruyère, O., Locquet, M., Gillain, S., Monseur, C., Reginster, J.-Y., & Beaudart, C. (2020). Development of a short version of the sarcopenia quality of life (SARQOL®) questionnaire. Osteoporosis International, 31 (S1), 450-451.

Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2020). Evaluating quality of life in frailty: applicability and psychometric properties of the SARQOL® questionnaire. Osteoporosis International, 31 (S1), 450.

Hiligsmann, M., Dennison, E., Beaudart, C., Herrero-Beaumont, G., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Al-Daghri, N., Jiwa, F., Lems, W., Pinto, D., Rizzoli, R., Thomas, T., Uebelhart, D., Veronese, N., & Reginster, J.-Y. (2020). A discrete-choice experiment to assess patients’preferences for osteoarthritis treatment: an ESCEO working group. Seminars in Arthritis and Rheumatism, 50 (5), 859-866. doi:10.1016/j.semarthrit.2020.08.005

Hiligsmann, M., Maggi, S., Onder, G., Galluzzo, L., & Reginster, J.-Y. (2020). Cost-effectiveness of BINISTO (buffered soluble alendronate 70 mg) effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 31 (S1), 58.

Kanis, J. A., Cooper, C., Dawson-Hughes, B., Harvey, N. C., Johansson, H., Lorentzon, M., McCloskey, E. V., Reginster, J.-Y., & Rizzoli, R. (2020). FRAX and ethnicity. Osteoporosis International, 31, 2063-2067. doi:10.1007/s00198-020-05631-6

Kanis, J. A., Harvey, N. C., McCloskey, E. V., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, M. K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, O., ... Reginster, J.-Y. (2020). ESCEO-IOF algorithm for the management of low/high/very high risk of fracture. Osteoporosis International, 31 (S1), 33.

Lengele, L., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). 5-year adverse outcomes of sarcopenia diagnosed according to six different definitions. Osteoporosis International, 31 (S1), 47-48.

Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., Boonen, A., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2020). An updated systematic review of cost-effectiveness analysis of drugs for osteoporosis. Osteoporosis International, 31 (S1), 491.

Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Croisier, J.-L. (2020). Muscle strengthevaluated using the hand-held dynamometer MicroFET2 in older adults: a reliability study. Osteoporosis International, 31 (S1), 301-302.

Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R., Cooper, C., Cortet, B., Diez-Perez, A., Ferrari, S., Gasparik, A., Herrman, M., Jorgensen, N. R., Kanis, J. A., Kaufman, J. M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E. V., Minisola, S., ... CAVALIER, E. (2020). Clinical application of bone turnover markers in postmenopausal osteoporosis. Osteoporosis International, 31 (S1), 65-66.

Mavungu Landu, D. J., Marini Djang'Eing'A, R., Hubert, P., Frederich, M., Michel, B., Gretry, L., Messina Ndzomo, J. P., Bruyère, O., Reginster, J.-Y., & Manzambi Kuwekita, J. (2020). Les déterminants de l’accès à des médicaments antipaludiques de qualité en territoires périurbains africains : résultats d’une enquête menée à Kinshasa (Congo). Journal d’Épidémiologie et de Santé Publique, 21, 85-100.

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., & Grauer, A. (2020). A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporosis International, 31 (11), 2231-2241. doi:10.1007/s00198-020-05502-0

McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Ruiz-Santiago, N., Shi, Y., Rojeski, M., Timoshanko, J., Libanati, C., Kassahun, H., & Oates, M. (2020). Romosozumab after Denosumab improves lumbar spine and maintains total hip bone mineral density in postmenopausal women with low bone mass. Osteoporosis International, 31 (S1), 41-42.

Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petir-Dop, F., Chapurlat, R., Reginster, J.-Y., Inskip, H., & Cooper, C. (2020). Improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoporosis International, 31 (S1), 524.

Reginster, J.-Y. (2020). What’s makes a difference between SYSADOAs. Osteoporosis International, 31 (S1), 624.

Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., Kaufman, J.-M., Lambrinoudaki, I., Laslop, A., McCloskey, E., Palacios, S., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Rosano, G., ... Harvey, N. C. (2020). Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporosis International, 31, 2271-2286. doi:10.1007/s00198-020-05497-8

Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., Barreto, P. D. S., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Erratum to: Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines (The journal of nutrition, health & aging, (2020), 10.1007/s12603-020-1492-3). Journal of Nutrition, Health and Aging. doi:10.1007/s12603-020-1547-5

Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., De Souto Barreto, P., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines. Journal of Nutrition, Health and Aging, 24 (9), 920-927. doi:10.1007/s12603-020-1492-3

Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., Cavalier, E., Bruyère, O., & Beaudart, C. (2020). Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. Journal of Cachexia, Sarcopenia and Muscle, 11 (5), 1200-1211. doi:10.1002/jcsm.12574

Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., CAVALIER, E., Bruyère, O., & Beaudart, C. (2020). Diagnosis of malnutrition using GLIM criteria : validity of 7 pragmatic approaches which do not require the measurement of muscle mass. Osteoporosis International, 31 (S1), 618.

Veronese, N., Cacco, C., Smith, L., Dermutas, J., Cooper, C., Reginster, J.-Y., Barbagallo, M., & Maggi, S. (2020). Dietary acrylamide and incident osteoporotic fractures: an 8-year longitudinal cohort study. Osteoporosis International, 31 (S1), 383.

Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Beaudart, C., Honvo, G., & Maggi, S. (2020). Glucosamine sulphate: an umbrella review of health outcomes. Therapeutic Advances in Musculoskeletal Disease, 12, 1-12. doi:10.1177/1759720X20975927

Veronese, N., Demurtas, J., Soysal, P., Smith, O., Bruyère, O., Reginster, J.-Y., Beaudart, C., Cooper, C., Mirko, M., & Maggi, S. (2020). Sarcopenia and health-related outcomes: an umbrella review of observational studies. Osteoporosis International, 31 (S1), 198-199.

Gillain, S., Boutaayamou, M., Schwartz, C., BRUYERE, O., Bruls, O., CROISIER, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (October 2019). Using supervised learning machine algorithm to identify future fallers based on gait patterns: a two-year longitudinal study [Poster presentation]. XXIIèmes Journées d'Automne de la SBGG, LIEGE, Belgium.

Gillain, S., Boutaayamou, M., Schwartz, C., Dardenne, N., BRUYERE, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & Petermans, J. (October 2019). Identify future fallers based on gait symmetry dual task changes: a two-year longitudinal study [Poster presentation]. 22èmes Journées d'Automne de la SBGG, LIEGE, Belgium.

Geerinck, A., Alekna, V., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (29 April 2019). Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. PLoS ONE, 14 (4). doi:10.1371/journal.pone.0216065

LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., Bruyère, O., & CAVALIER, E. (April 2019). Risk-fracture prediction in elderly people based on a microRNA panel [Poster presentation]. IOF-WHO osteoporosis congress.

Bruyère, O., Beaudart, C., Ethgen, O., Reginster, J.-Y., & Locquet, M. (2019). The health economics burden of sarcopenia: a systematic review. Maturitas, 119, 61-9. doi:10.1016/j.maturitas.2018.11.003

Bruyère, O., Reginster, J.-Y., Honvo, G., & Detilleux, J. (2019). Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clinical and Experimental Research, 31 (6), 881-887. doi:10.1007/s40520-019-01138-1

Charles, A., Buckinx, F., Locquet, M., Reginster, J.-Y., PETERMANS, J., Gruslin, B., & Bruyère, O. (2019). Intrinsic capacity and its association with mortality over 3 years in nursing homes: Results of the SENIOR cohort. Osteoporosis International, 30 (S2), 177-178.

GILLAIN, S., Boutaayamou, M., Schwartz, C., Dardenne, N., Bruyère, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (2019). Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. Aging Clinical and Experimental Research, 31 (8), 1057-1067. doi:10.1007/s40520-019-01210-w

GILLAIN, S., Boutaayamou, M., Schwartz, C., WOJTASIK, V., CHRISTELBACH, S., Dardenne, N., Bruls, O., Bruyère, O., Reginster, J.-Y., CROISIER, J.-L., GARRAUX, G., & PETERMANS, J. (June 2018). Dépister les sujets à risque de chute parmi nos aînés robutes: intérêt de la marche rapide [Poster presentation]. Congrès de la CIFGG, Montreux, Switzerland.

Buckinx, F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Kaux, J.-F. (2018). French cross-cultural adaptation and measurement properties of the “ANTERIOR KNEE PAIN SCALE”. In Abstract Book - 21st European Congress of Physical and Rehabilitation Medicine (pp. 399).

Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S., Weiss, R., & Reginster, J.-Y. (April 2018). Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for the prevention of osteoporotic fractures in postmenopausal women at increased risk of fracture. Osteoporosis International, 29 S1, 302.

Buckinx, F., Landi, F., Cesari, M., Fielding, R., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M.-L., Bruyère, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. (2018). The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al. Journal of Cachexia, Sarcopenia and Muscle, 9 (7), 1272-1274. doi:10.1002/jcsm.12387

Dierks, R. M. L., Bruyère, O., & Reginster, J.-Y. (2018). Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 18 (2), 147-60. doi:10.1080/14737167.2018.1417040

Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2018). Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 29, 1505-1510. doi:10.1007/s00198-018-4504-y

Slomian, J., Vigneron, L., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2018). Evaluation du site internet Happy-Mums.be conçu en vue de tenter d’aider les mères à combler leurs besoins en période postnatale [Poster presentation]. 46ème Assises Nationales des Sages-Femmes, Marseille, France.

Mavungu Landu, D. J., Mikobi Mikobi, C., Beya, R., Pipo Tshiasuma, M., Kayembe, J. M., Gretry, L., Marini Djang'Eing'A, R., Hubert, P., Reginster, J.-Y., Michel, B., Manzambi Kuwekita, J., & Frederich, M. (10 November 2017). Expérience de l’intégration des cours de Médecine traditionnelle dans la Faculté de Médecine de l’Université Notre-Dame du Kasayi à Kananga [Paper presentation]. Médecines en Afrique, entre tradition et modernité, Liège, Belgium.

Buckinx, F., Reginster, J.-Y., Morelle, A., Paquot, N., Labeye, N., Locquet, M., Adam, S.* , & Bruyère, O.*. (04 July 2017). Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. Clinical Interventions in Aging, 12, 1055-1064. doi:10.2147/CIA.S135937

Al-Daghri, N., Al-Saleh, Y., Aljohani, N., Sulimani, R., Al-Othman, A., Alfawaz, H., Fouda, M., Al-Amri, F., Shahrani, A., Alharbi, M., ALSHAHRANI, F., Tamini, W., Sabico, S., Rizzoli, R., & Reginster, J.-Y. (2017). Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Archives of Osteoporosis, 12, 1. doi:10.1007/s11657-016-0295-y

Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (January 2017). Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS ONE, 12 (1), 0169548. doi:10.1371/journal.pone.0169548

Bruyère, O., CAVALIER, E., & Reginster, J.-Y. (2017). Vitamin D and osteosarcopenia: an update from epidemiological studies. Current Opinion in Clinical Nutrition and Metabolic Care, 20 (6). doi:10.1097/MCO.0000000000000411

Hiligsmann, M., Neuprez, A., Buckinx, F., Locquet, M., & Reginster, J.-Y. (2017). A scoping review of the public health impact of vitamin D - fortified dairy products for fracture prevention. Archives of Osteoporosis, 12, 57. doi:10.1007/s11657-017-0352-1

Slomian, J., Emonts, P., Vigneron, L., Acconcia, A., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (2017). Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. JMIR Research Protocols, 6 (5), 76. doi:10.2196/resprot.6831

Neuprez, A., Delcour, J.-P., Fatemi, F., Gillet, P., Crielaard, J.-M., Bruyère, O., & Reginster, J.-Y. (15 December 2016). Patients' expectations impact their satisfaction following total hip or knee arthroplasty. PLoS ONE, 11 (12), 1-14. doi:10.1371/journal.pone.0167911

Buckinx, F., PAQUOT, N., FADEUR, M., Bacus, L., Reginster, J.-Y., ALLEPAERTS, S., PETERMANS, J., Biquet, S., & Bruyère, O. (10 November 2016). Assessment of energy expenditure of nursing home residents with indirect calorimetry [Paper presentation]. International Nursing Home Research Conference - International Working Group, Barcelone, Spain.

Buckinx, F., Morelle, A., Adam, S., Reginster, J.-Y., Labeye, N., Locquet, M., & Bruyère, O. (29 September 2016). Influence of environmental factors on food intakes of nursing home residents: a survey combined to a video approach [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (29 September 2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (29 September 2016). Identification de solutions technologiques potentielles en réponse aux besoins des mères dans l'année suivant leur accouchement [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Slomian, J., EMONTS, P., Vigneron, L., Acconcia, A., Glowacz, F., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (May 2016). Identification des besoins des mères dans l’année suivant leur accouchement : une étude qualitative [Poster presentation]. 44èmes Assises Nationales des Sages-Femmes, Saint-Malo, France.

Detilleux, J., REGINSTER, J.-Y., Chines, A., & Bruyère, O. (2016). A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Statistical Methods in Medical Research, 25 (1), 400-412. doi:10.1177/0962280212456655

Ferrari, S., Reginster, J.-Y., Brandi, M. L., Kanis, J. A., Devogelaer, J. P., Kaufmann, J. P., Feron, J. M., Kurth, A., & Rizzoli, R. (2016). Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Archives of Osteoporosis, 11, 37. doi:10.1007/s11657-016-0292-1

SMOLEN, J. S., COLLAUD BASSET, S., BOERS, M., BREEDVELD, F., EDWARDS, C. J., KVIEN, T. K., MIOSSEC, P., SOKKA-ISLER, T., van VOLLENHOVEN, R. F., Abadie, E. C., Bruyère, O., COOPER, C., MÄKINEN, H., THOMAS, T., TUGWELL, P., & Reginster, J.-Y. (2016). Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 75, 1268-1271. doi:10.1136/annrheumdis-2016-209429

Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & Reginster, J.-Y. (30 December 2015). Le couplage « Micro-crédit, Micro-assurance santé et Offre des soins » peut améliorer l’accessibilité aux soins de santé de qualité en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Médecine et Santé Tropicales, 25, 381-385. doi:10.1684/mst.2015.0520

Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (2015). Le tradipraticien est un acteur incontournable dans l’offre des soins de santé en territoire péri-urbain : équilibre entre légitimité et illégalité ? In J.-M. Halleux & J. Bogaert (Ed.), Territoires Périurbains (Cette oeuvre est sous licence Creative Commons. Vous êtes libre de reproduire, de modifier, de distribuer et de communiquer cette création au public selon les conditions suivantes : • paternité (BY) : vous devez citer le nom de l’auteur original de la manière indiquée par l’auteur de l’oeuvre ou le titulaire des droits qui vous confère cette autorisation (mais pas d’une manière qui suggérerait qu’ils vous soutiennent ou approuvent votre utilisation de l’oeuvre) ; • pas d’utilisation commerciale (NC) : vous n’avez pas le droit d’utiliser cette création à des fins commerciales ; • partage des conditions initiales à l’identique (SA) : si vous modifiez, transformez ou adaptez cette création, vous n’avez le droit de distribuer la création qui en résulte que sous un contrat identique à celui-ci. À chaque réutilisation ou distribution de cette création, vous devez faire apparaître clairement au public les conditions contractuelles de sa mise à disposition. Chacune de ces conditions peut être levée si vous obtenez l’autorisation du titulaire des droits sur cette oeuvre. Rien dans ce contrat ne diminue ou ne restreint le droit moral de l’auteur, pp. 184-193). Gembloux, Belgium: Presses Agronomiques de Gembloux.

Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., PETERMANS, J., GILLAIN, S., Buckinx, F., & Bruyère, O. (17 November 2015). Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQoL [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Bruyère, O., Reginster, J.-Y., Dardenne, N., Nelis, J., Lambert, E., Appelboom, G., & Buckinx, F. (17 November 2015). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Locquet, M., Beaudart, C., LARBUISSON, R., Buckinx, F., KAUX, J.-F., Reginster, J.-Y., & Bruyère, O. (17 November 2015). Prevalence and factors associated with self-medication practice among amateur runners [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (17 November 2015). Identification des besoins d'une mère dans l'année suivant son accouchement : comparaison entre les femmes ayant vécu au moins un épisode de détresse psychologique et celles n'en ayant pas vécu [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

GILLAIN, S., Petermans, J., Dardenne, N., Beaudart, C., Buckinx, F., GARRAUX, G., REGINSTER, J.-Y., Bruyère, O., DEMONCEAU, M., WOJTASIK, V., & Schwartz, C. (April 2015). Comparison of body composition, muscle force and physical performances between faller and non-faller people included in a cohort of 100 community dwelling volunteers : the Gaby Study. Journal of Frailty and Aging, 4 (S1), 106.

Manzambi Kuwekita, J., Eloko Eya Matangelo, G., Bruyère, O., Gosset, C., Guillaume, M., & Reginster, J.-Y. (31 March 2015). Financement de la santé et recouvrement des coûts : le lourd fardeau des ménages congolais. Résultats des comptes nationaux de la santé. Journal d’Épidémiologie et de Santé Publique, 15 (Mars 2015), 15-27.

Manzambi Kuwekita, J., Bruyère, O., Guillaume, M., Gosset, C., & Reginster, J.-Y. (23 March 2015). Comment optimiser l’efficience de l’aide internationale, dans le domaine de la santé, en République Démocratique du Congo. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 27 (Janvier-Févier), 129-134. doi:10.3917/spub.151.0129

GILLAIN, S., Schwartz, C., Boutaayamou, M., Demonceau, M., CROISIER, J.-L., Bruls, O., GARRAUX, G., REGINSTER, J.-Y., & PETERMANS, J. (October 2014). Validation des paramètres de marche par un système accélérométrique (Locométrix*) à l'aide d'un système opto-électronique 3D (Coda Motion ). Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (supplément 3).

Manzambi Kuwekita, J., Bruyère, O., & REGINSTER, J.-Y. (31 March 2014). Le rôle du tradipraticien dans l’offre des soins de sante de proximité en zones de sante semi-rurales : résultats d’une étude menée dans la commune périphérique de Kisenso à Kinshasa, Congo. Journal d’Épidémiologie et de Santé Publique, XIII, 59-66.

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53.

Manzambi Kuwekita, J., Bruyère, O., REGINSTER, J.-Y., Buhendwa, E., Bokanga, R., & Mwanyimi, P. (19 December 2013). Les acteurs non étatiques jouent un rôle déterminant dans le fonctionnement des services publics en territoires périurbains [Poster presentation]. Territoires périurbains: développement, enjeux et perspectives dans les pays du Sud, Gembloux, Belgium.

Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (19 December 2013). Le tradipraticien est un acteur crédible dans l'offre des soins en territoire périurbain: Résultats d'une étude menée dans la commune de Kisenso à Kinshasa, Congo [Paper presentation]. Colloque Territoires périurbains: Développement, Enjeux et Perspectives dans les Pays du Sud, Gembloux, Belgium.

Manzambi Kuwekita, J., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Mayamba Kilela, J., Bruyère, O., & Reginster, J.-Y. (December 2013). Étude des conditions de vie et d’accessibilité aux soins de santé de qualité des populations en situation de précarité, dans la zone de sante de Bandalungwa à Kinshasa (Congo) grâce à la micro-assurance santé en 2008. Journal d’Épidémiologie et de Santé Publique, 12, 47-61.

Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Les effets d’une supplémentation en vitamine D sur la force musculaire : une méta-analyse d’essais randomisés contrôlés [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Buckinx, F., Beaudart, C., Maquet, D., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Etude de l'impact d'un entraînement de 6 mois par vibrothérapie sur le risque de chute, observé pendant une durée d'un an, chez les patients résidant en maison de repos. Etude randomisée contrôlée menée en simple aveugle [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium.

Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Nsita Zaya Nsita, B., Tshefu Pongo, G., Eloko Eya Matangelo, G., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & REGINSTER, J.-Y. (30 September 2013). Micro-crédit, Augmentation du pouvoir d’achat et Amélioration des conditions de vie des populations précaires en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Psychologie et Société Nouvelle, XII (3), 3-14.

Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Financement de la Santé et Extension de la Protection Sociale dans les Pays en Développement - L'expérience du PNPS à Bandalungwa, Kinshasa, Congo. Liège, Belgium: Les Editions du Céfal.

Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Perception et comportement de recours aux soins de santé dans les pays en voie de développement. Le cas de la République Démocratique du Congo. (Tous droits de reproduction, d'adaptation et de traduction réservés pour tous pays). Liège, Belgium: Les Editions du Céfal.

Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents. BMC Geriatrics, 13 (42). doi:10.1186/1471-2318-13-42

Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., CAVALIER, E., GILLAIN, S., Petermans, J., & REGINSTER, J.-Y. (2013). Prevalence of vitamin D inadequacy in European postmenopausal women aged over 80 years. European Geriatric Medicine, 4 (S1), 13-S14.

COLSON, L., Vander Rest, C., Reginster, J.-Y., DELANAYE, P., CAVALIER, E., LE GOFF, C., Crielaard, J.-M., & Kaux, J.-F. (December 2012). Ostéomalacie hypophosphatémique hyperphosphaturique avec hypersécrétion de FGF-23. Lettre du Rhumatologue, 387, 26-29.

Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (20 November 2012). Evaluation de l'impact d'un entraînement de trois mois par vibrotonie sur le risque de chute chez des patients résidant en maison de repos [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium.

Bruyère, O., Demoulin, M., Brereton, C., Humblet, F., Flynn, D., Hill, J. C., Maquet, D., Van Beveren, J., Reginster, J.-Y., CRIELAARD, J.-M., & Demoulin, C. (June 2012). Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French. Archives of Public Health, 70. doi:10.1186/0778-7367-70-12

Hiligsmann, M., Boonen, A., Rabenda, V., & REGINSTER, J.-Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), 159-66. doi:10.1586/erp.12.8

Hiligsmann, M., & Reginster, J.-Y. (2012). Un monde médical et économique en pleine évolution : maladies complexes et intérêt de l’évaluation économique des technologies de santé. Revue Médicale de Liège, 67 (5-6), 258-262.

VAN DER REST, C., CAVALIER, E., COLSON, L., KAUX, J.-F., KRZESINSKI, J.-M., REGINSTER, J.-Y., HUSTINX, R., & DELANAYE, P. (August 2011). Hypophosphatémie et ostéomalacie oncogénique. Revue Médicale Suisse, 7, 1630-3.

Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Hollevoet, N., Kaufman, J.-M., Milisen, K., Rozenberg, S., & Reginster, J.-Y. (2011). Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporosis International, 22 (11), 2769-88. doi:10.1007/s00198-011-1545-x

Chapurlat, R., Bone, H. G., Brandi M L, Brown, J. P., Czerwinski, E., Daizadeh, N. S., Grauer, A., Krieg, M. A., Libanati, C., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., & Resch, H. (2011). Treatment of postmenopausal women with osteoporosis for 5 years with denosumab : two-year results from the FREEDOM trial extension. Annals of the Rheumatic Diseases, 70 (S3), 166-167.

Hiligsmann, M., & Reginster, J.-Y. (2011). Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics, 29 (10), 895-911. doi:10.2165/11539980-000000000-00000

Johansson, H., Kanis, J. A., McCloskey, E. V., Oden, A., Devogelaer, J. P., Kaufman, J. M., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2011). A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporosis International, 22 (2), 453-61. doi:10.1007/s00198-010-1218-1

Miossec, P., Verweij, C. L., Klareskog, L., Pitzalis, C., Barton, A., Lekkerkerker, F., Reiter, S., Laslop, A., Breedveld, F., Abadie, E., Flamion, B., Dere, W., Mpofu, S., Goel, N., Ethgen, O., Mitlak, B., Ormarsdottir, S., RAO, R. F., Tsouderos, Y., & Reginster, J.-Y. (2011). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 70 (10), 1713-8. doi:10.1136/ard.2011.154252

Reginster, J.-Y. (2011). Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs, 71 (1), 65-78. doi:10.2165/11587570-000000000-00000

Reginster, J.-Y., Kaufman, J. M., Devogelaer, J. D., Benhamou, C. L., & Roux, C. (2011). Long-term treatment of postmenopausal osteoporotic women with strontium ranelate : results at 10 years. Annals of the Rheumatic Diseases, 70 (S3), 167.

Bruyère, O., Collette, J., & Reginster, J.-Y. (June 2010). Long-term effect of strontium ranelate on serum C-terminal propeptide of type I Procollagen (PICP) and urine cross-linked N-telopeptide (U-NTX) in women with postmenopausal osteoporosis. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602.

Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469.

Collette, J., Bruyère, O., Vanoverberghe, M., & Reginster, J.-Y. (June 2010). Effect of strontium ranelate on serum osteoprotegerin in women with postmenopausal osteoporosis treated over three years. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602.

Reginster, J.-Y. (June 2010). Preparing new regulatory guidelines: the role of the Group for the Respect of Ethics and Excellence in Science (GREES). Annals of the Rheumatic Diseases, 69 (Suppl.3), 42.

Bergmann, P., Body, J. J., BOONEN, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J., Reginster, J.-Y., & Rozenberg, S. (2010). Loading and skeletal development and maintenance. Journal of Osteoporosis, 2011, 786752. doi:10.4061/2011/786752

Rabenda, V., & Reginster, J.-Y. (2010). Prévention et traitement de l’ostéoporose: éviter l’inertie clinique et motiver l’adhésion au traitement. Revue Médicale de Liège, 65, 358-365.

Reginster, J.-Y. (2010). National implementation of the ESCEO guidance and its consequences. Medicographia, 32, 67-70.

Reginster, J.-Y., Altman, R. D., & Hochberg, M. C. (2010). Prescribed regimen is effective [letter to the editor]. BMJ: British Medical Journal, 341, 6335. doi:10.1136/bmj.c6335

Scheen, A., Hanssens, L., Wampers, M., Van Winkel, R., Collette, J., Reginster, J.-Y., & de Hert, M. A. (2010). Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités. In Diabetes and Metabolism (pp. 21, O78). Elsevier.

Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufmann, J.-M., & Reginster, J.-Y. (December 2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. Revue Médicale de Liège, 64 (12), 612-619.

Hiligsmann, M., Rabenda, V., & Reginster, J.-Y. (June 2009). The clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients. Annals of the Rheumatic Diseases, 68 (S3), 667.

Bruyère, O., DeCock, C., Mottet, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (2009). Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutrition, 12 (1), 111-114. doi:10.1017/S1368980008002024

Kaux, J.-F., Le Goff, C., Debray, F.-G., Crielaard, J.-M., & Reginster, J.-Y. (2009). Le cas clinique du mois. Osteogenesis imperfecta. Revue Médicale de Liège.

NEUPREZ, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2009). Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne. Revue Médicale de Liège, 64 (10), 525-9.

Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421.

Bruyère, O., Brandi, M., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (June 2008). Relationship between long-term changes in femoral neck bone mineral density and hip fracture incidence in untreated postmenopausal osteoporotic women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403.

Bruyère, O., Collette, J., Christiansen, F., Fardellone, F., Detroz, A., Deroisy, R., & Reginster, J.-Y. (June 2008). Association between lumbar disc degeneration and biochemical markers of bone and cartilage remodelling. Annals of the Rheumatic Diseases, 67 (Suppl.II), 231.

Bruyère, O., Delhez, M., Collette, J., & Reginster, J.-Y. (June 2008). Prevalence of vitamin D inadequacy in institutionalized osteoporotic postmenopausal women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403.

Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428.

Bruyère, O., Roces-Varela, A., Adami, S., & Reginster, J.-Y. (June 2008). Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 89.

Reginster, J.-Y., Barr, C. E., Blumentals, W. A., & Harris, S. T. (June 2008). Similar non-vertebral antifracture efficacy demonstrated with monthly ibandronate versus weekly bisphosphonate therapy: A retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539.

Reginster, J.-Y., Boisdron, J., & Barr, C. E. (June 2008). Vertebral fracture efficacy of monthly ibandronate versus weekly bisphosphonates: analysis of a retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539.

Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M. L., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., Balogh, A., Delmas, P. D., & Meunier, P. J. (June 2008). Strontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk. Annals of the Rheumatic Diseases, 67 (Suppl.II), 540.

Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (June 2008). A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 56.

Saag, K. G., Devogelaer, J.-P., Reid, D. M., Sambrook, P., Goemaere, S., Ish-Shalom, S., Collette, J., Papanastasiou, P., Ferreira, A., Eriksen, E. F., Fashola, T., Schoenborn-Kellenberger, O., Chappard, D., & Reginster, J.-Y. (June 2008). Effects of a single 5 mg infusion of zoledronic acid and oral risedronate (5 mg/day) on bone remodeling over one year in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 542.

Bruyère, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J.-P., Brixen, K., Adami, S., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (March 2008). Effects of Strontium Ranelate on Spinal Osteoarthritis Progression. Annals of the Rheumatic Diseases, 67 (3), 335-9. doi:10.1136/ard.2007.075572

Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021

Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (February 2008). Total Joint Replacement after Glucosamine Sulphate Treatment in Knee Osteoarthritis: Results of a Mean 8-Year Observation of Patients from Two Previous 3-Year, Randomised, Placebo-Controlled Trials. Osteoarthritis and Cartilage, 16 (2), 254-60. doi:10.1016/j.joca.2007.06.011

Bruyère, O., Burlet, N., Delmas, P. D., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2008). Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders, 9, 165. doi:10.1186/1471-2474-9-165

Fleischmann, R., Tannenbaum, H., Patel, N. P., Notter, M., Sallstig, P., & Reginster, J.-Y. (2008). Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders, 9, 32. doi:10.1186/1471-2474-9-32

Goldhahn, J., Mitlak, B., Aspenberg, P., Kanis, J. A., Rizzoli, R., & Reginster, J.-Y. (2008). Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. Journal of Bone and Joint Surgery. American Volume, 90 Suppl 1, 43-7. doi:10.2106/JBJS.G.01090

Hanssens, L., Scheen, A., van Winkel, R., Van Eyck, D., Reginster, J.-Y., & De Hert, M. (2008). Le cerveau au centre des regulations metaboliques: anomalies chez les patients schizophrenes traites par antipsychotiques atypiques. Revue Médicale de Liège, 63 (5-6), 417-23.

Hanssens, L., van Winkel, R., Wampers, M., Van Eyck, D., Scheen, A., Reginster, J.-Y., Collette, J., Peuskens, J., & De Hert, M. (2008). A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 106 (2-3), 308-14. doi:10.1016/j.schres.2008.09.008

Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (2008). Evaluation économique de la campagne de dépistage de l'ostéoporose menée en Province de Liège avec le concours de Liège Province Santé. Revue Médicale de Liège, 63 (10), 588-94.

Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2008). Risque à long terme de survenue d'une fracture ostéoporotique en Belgique. Revue Médicale de Liège, 63 (7-8), 480-487.

Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Low incidence of anti-osteoporosis treatment after hip fracture. Journal of Bone and Joint Surgery. American Volume, 90 (10), 2142-8. doi:10.2106/JBJS.G.00864

Reginster, J.-Y. (November 2007). Le ranelate de strontium (Protelos). Revue Médicale de Liège, 62 (11), 685-7.

Lekkerkerker, F., Kanis, J. A., Alsayed, N., Bouvenot, G., Burlet, N., Cahall, D., Chines, A., Delmas, P., Dreiser, R. L., Ethgen, D., Hughes, N., Kaufman, J. M., Korte, S., Kreutz, G., Laslop, A., Mitlak, B., Rabenda, V., Rizzoli, R., Santora, A., ... Reginster, J.-Y. (October 2007). Adherence to treatment of osteoporosis: a need for study. Osteoporosis International, 18 (10), 1311-1317. doi:10.1007/s00198-007-0410-4

Bruyère, O., Roux, C., Detilleux, J., Slosman, D. O., Spector, T. D., Fardellone, P., Brixen, K., Devogelaer, J. P., Diaz-Curiel, M., Albanese, C., Kaufman, J. M., Pors-Nielsen, S., & Reginster, J.-Y. (August 2007). Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. Journal of Clinical Endocrinology and Metabolism, 92 (8), 3076-3081. doi:10.1210/jc.2006-2758

Malaise, O., Bruyère, O., & Reginster, J.-Y. (August 2007). Strontium ranelate normalizes bone mineral density in osteopenic patients. Aging Clinical and Experimental Research, 19 (4), 330-333. doi:10.1007/BF03324710

Bruyère, O., Delferriere, D., Roux, C., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (July 2007). Positive effects of strontium ranelate on spine osteoarthritis progression. Annals of the Rheumatic Diseases, 66 (Suppl.II), 58.

Reginster, J.-Y. (July 2007). The efficacy of glucosamine sulfate in osteoarthritis: Financial and nonfinancial conflict of interest. Arthritis and Rheumatism, 56 (7), 2105-2110. doi:10.1002/art.22852

Reginster, J.-Y., Malmstrom, K., Mehta, A., Bergman, G., Ko, A. T., Curtis, S. P., & Reicin, A. S. (July 2007). Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Annals of the Rheumatic Diseases, 66 (7), 945-951. doi:10.1136/ard.2006.059162

Bruyère, O., Roux, C., Detilleux, J., & Reginster, J.-Y. (June 2007). Increase in femoral neck bone mineral density is associated with decrease in vertebral and hip fracture incidence during a 3-year treatment with strontium ranelate. Annals of the Rheumatic Diseases, 66 (Suppl.II), 521.

MacDonald, T., Littlejohn, T., Richard, D., Lheritier, K., Krammer, G., & Reginster, J.-Y. (June 2007). Improved blood pressure control but similar efficacy with lumiracoxib 100 mg OD compared to ibuprofen 600 mg TID in hypertensive patients with osteoarthritis: randomised controlled trial. Annals of the Rheumatic Diseases, 66 (Suppl.II), 502.

Reginster, J.-Y., Brixen, K., Cormier, C., & Cannata Andia, J. B. (June 2007). Long term efficacy of strontium ranelate in reducing the risk of vertebral and non-vertebral including hip fractures in post menopausal osteoporotic women over 5 years. Annals of the Rheumatic Diseases, 66 (Suppl.II), 102.

Neuprez, A., Bruyère, O., Collette, J., & Reginster, J.-Y. (26 April 2007). Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. BMC Public Health, 7 (147), 64. doi:10.1186/1471-2458-7-64

Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (February 2007). Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clinical and Experimental Research, 19 (1), 55-60. doi:10.1007/BF03325211

Bruyère, O., & Reginster, J.-Y. (2007). Structure modification in osteoarthritis. European Musculoskeletal Review, 27-30.

Bruyère, O., & Reginster, J.-Y. (2007). Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip Osteoarthritis. Drugs and Aging, 24 (7), 573-580. doi:10.2165/00002512-200724070-00005

Neuprez, A., Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (2007). Prevention of hip fractures in osteoporosis. Minerva Ortopedica e Traumatologica, 58 (5), 423-437.

Reginster, J.-Y. (2007). Bone Forming Angents. European Musculoskeletal Review, 90-92.

Reginster, J.-Y. (2007). Actualites therapeutiques dans le traitement de l'osteoporose postmenopausique. Revue Médicale de Liège, 62 (5-6, May-Jun), 352-9.

Reginster, J.-Y., Malaise, O., NEUPREZ, A., Jouret, V. E., & Close, P. (2007). Intermittent bisphosphonate therapy in postmenopausal osteoporosis - Progress to date. Drugs and Aging, 24 (5), 351-359. doi:10.2165/00002512-200724050-00001

Reginster, J.-Y. (November 2006). L'ibandronate (Bonviva), dans le traitement de l'osteoporose postmenopausique. Revue Médicale de Liège, 61 (11), 783-6.

Altman, R. D., Abramson, S., Bruyère, O., Clegg, D., Herrero-Beaumont, G., Maheu, E., Moskowitz, R., Pavelka, K., & Reginster, J.-Y. (October 2006). Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage, 14 (10), 963-966. doi:10.1016/j.joca.2006.06.010

Bruyère, O., Collette, J., Kothari, M., Zaim, S., White, D., Genant, H., Peterfy, C., Burlet, N., Ethgen, D., Montague, T., Dabrowski, C., & Reginster, J.-Y. (August 2006). Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Annals of the Rheumatic Diseases, 65 (8), 1050-1054. doi:10.1136/ard.2005.045914

Czerwinski, E., Nuti, R., Greenwald, M., Burdeska, A., Leigh, C., & Reginster, J.-Y. (June 2006). Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis. Annals of the Rheumatic Diseases, 65 (Suppl.II), 415.

Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J.-Y., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., Bolognese, M., Hughes, C., Masanauskaite, D., Ward, P., Sambrook, P., & Reid, D. M. (June 2006). Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study. Arthritis and Rheumatism, 54 (6), 1838-1846. doi:10.1002/art.21918

Reginster, J.-Y., Hawker, G., Bolognese, M., Coutant, K., Hughes, C., Sedarati, F., & Stone, M. (June 2006). Influence of baseline patient characteristics on response to one-monthly and daily oral ibandronate therapy: 2-year findings from MOBILE. Annals of the Rheumatic Diseases, 65 (Suppl.II), 426.

Reginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., Drezner, M. K., Emkey, R., Felsenberg, D., Cooper, C., Delmas, P. D., & Miller, P. D. (May 2006). Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases, 65 (5), 654-661. doi:10.1136/ard.2005.044958

NEUPREZ, A., Gillet, P., Collette, C., & Reginster, J.-Y. (April 2006). L'osteodensitometrie dans le depistage de l'osteoporose: le paradoxe Belge. Revue Médicale de Liège, 61 (4), 249-55.

Reginster, J.-Y., Richy, F., & Bruyère, O. (March 2006). Activite antalgique de la glucosamine dans l'arthrose: quoi de neuf en 2006? Revue Médicale de Liège, 61 (3), 169-72.

Hanssens, L., De Hert, M., Wampers, M., Reginster, J.-Y., & Peuskens, J. (2006). Pharmacological Treatment of Ambulatory Schizophrenic Patients in Belgium. Clinical Practice and Epidemiology in Mental Health, 2, 11. doi:10.1186/1745-0179-2-11

Reginster, J.-Y. (2006). Intravenous ibandronate in the treatment of osteoporosis: A viewpoint by Jean-Yves Rginster. Drugs, 66 (12), 1602-1602. doi:10.2165/00003495-200666120-00006

Reginster, J.-Y., & Rabenda, V. (2006). Patient Preference in the Management of Postmenopausal Osteoporosis with Bisphosphonates. Clinical Interventions in Aging, 1 (4), 415-23. doi:10.2147/ciia.2006.1.4.415

Reginster, J.-Y., & Sarlet, N. (2006). The Treatment of Severe Postmenopausal Osteoporosis : A Review of Current and Emerging Therapeutic Options. Treatments in Endocrinology, 5 (1), 15-23. doi:10.2165/00024677-200605010-00003

Richy, F., Lecart, M.-P., Mawet, A., Paquot, B., & Reginster, J.-Y. (2006). Interet de la densitometrie osseuse dans le depistage et le suivi therapeu- tique des patients osteoporotiques: integration avec les facteurs cliniques et biologiques. Revue Médicale de Liège, 61 (5-6, May-Jun), 291-300.

Bruyère, O., Richy, F., & Reginster, J.-Y. (December 2005). Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Annals of the Rheumatic Diseases, 64 (12), 1727-1730. doi:10.1136/ard.2005.037309

Reginster, J.-Y., Wilson, K. M., Dumont, E., Bonvoisin, B., & Barrett, J. (September 2005). Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study. Journal of Clinical Endocrinology and Metabolism, 90 (9), 5018-5024. doi:10.1210/jc.2004-1750

Reginster, J.-Y. (18 June 2005). Treatment of postmenopausal osteoporosis. BMJ: British Medical Journal, 330 (7505), 856-860. doi:10.1136/bmj.330.7496.859

Adami, S., Tanko, L. B., Nuti, R., Leigh, C., Mairon, N., Sedarati, F., & Reginster, J.-Y. (June 2005). Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE. Annals of the Rheumatic Diseases, 64 (Suppl.III), 364.

Cooper, C., Delmas, P. D., Felsenberg, D., Hughes, C., Mairon, N., Bonvoisin, B., & Reginster, J.-Y. (June 2005). Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study. Annals of the Rheumatic Diseases, 64 (Suppl.III), 68.

Reginster, J.-Y., Lorenc, R., Stepan, J. J., Hughes, C., Mairon, N., Bonvoisin, B., & Cooper, C. (June 2005). Once-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE. Annals of the Rheumatic Diseases, 64 (Suppl.III), 93.

Reginster, J.-Y., Nevitt, M. C., Chen, P., Dore, R. K., Kiel, D. P., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (June 2005). Reduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Annals of the Rheumatic Diseases, 64 (Suppl.III), 521.

Reginster, J.-Y., Richy, F., Rabenda, V., & Tancredi, A. (June 2005). Global prevalence and skeletal implications of vitamin D inadequacy. Annals of the Rheumatic Diseases, 64 (Suppl.III), 362.

Reginster, J.-Y., Stepan, J. J., Halse, J., Hughes, C., Mahoney, P., Masanauskaite, D., & Stakkestad, J. A. (June 2005). Intravenous ibandronate injections are at least as effective as daily oral ibandronate: consistent effect across subgroups. Annals of the Rheumatic Diseases, 64 (Suppl.III), 365.

Roux, C., Fardellone, P., Fechtenbaum, J., Kolta, S., Kruse, H., Sawicki, A., Hoszowski, K., Padrino, J. M., Sorensen, H., Reginster, J.-Y., & Meunier, P. (June 2005). Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status. Annals of the Rheumatic Diseases, 64 (Suppl.III), 359.

Rabenda, V., Burlet, N., Ethgen, O., Raeman, F., Belaiche, J., & Reginster, J.-Y. (May 2005). A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal antiinflammatory drugs. Annals of the Rheumatic Diseases, 64 (5), 688-693. doi:10.1136/ard.2004.026658

Reginster, J.-Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J. P., Curiel, M. D., Sawicki, A., Goemaere, S., Sorensen, O. H., Felsenberg, D., & Meunier, P. J. (May 2005). Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Journal of Clinical Endocrinology and Metabolism, 90 (5), 2816-2822. doi:10.1210/jc.2004-1774

Richy, F., Deroisy, R., Lecart, M.-P., Hanssens, L., Mawet, A., & Reginster, J.-Y. (April 2005). D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clinical and Experimental Research, 17 (2), 133-142. doi:10.1007/BF03324586

Bruyère, O., Edwards, J., & Reginster, J.-Y. (2005). what are the effects of treatments to prevent fractures in postmenopausal osteoporosis. BMJ Clinical evidence, 13, 325-327.

Bruyère, O., Edwards, J., & Reginster, J.-Y. (2005). Fracture prevention in postmenopausal women. Clinical Evidence, 13, 1419-1434.

Chevalier, T., Daures, J. P., Micheletti, M. C., Reginster, J.-Y., & Groupe MISSION. (2005). Méthodologie de l'enquête MISSION (Ménopause, risque de cancer du sein, morbidité et prévalence). Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 34 (7-C1), 658-665.

Reginster, J.-Y., Kaufman, J. M., & Gangjii, V. (2005). Preference for and acceptability of two formulations of a dietary supplement containing calcium plus vitamin D-3: A randomized, open-label, crossover trial in adult patients with calcium and vitamin D deficiencies. Current Therapeutic Research, 66 (1, JAN-FEB), 23-34. doi:10.1016/j.curtheres.2005.03.003

Reginster, J.-Y., & Devogelaer, J.-P. (November 2004). Traitement de l'osteoporose postmenopausique en 2004. Revue Médicale de Liège, 59 (11), 633-47.

Tannenbaum, H., Berenbaum, F., Reginster, J.-Y., Zacher, J., Robinson, J., Poor, P. G., Bliddal, H., Uebelhart, D., Adami, S., Navarro, F., Lee, A., Moore, A., & Gimona, A. (November 2004). Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Annals of the Rheumatic Diseases, 63 (11), 1419-1426. doi:10.1136/ard.2003.015974

Tancredi, A., Reginster, J.-Y., Schleich, F., Pire, G., Maassen, P., Luyckx, F., & Legros, J.-J. (September 2004). Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. European Journal of Endocrinology, 151 (3), 355-360. doi:10.1530/eje.0.1510355

Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Bouvenot, G., Audran, M., Herrero-Beaumont, G., Moore, A., Eliakim, R., Haim, M., & Reginster, J.-Y. (July 2004). Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach [letter to the editor]. Annals of the Rheumatic Diseases, 63 (7), 759-766. doi:10.1136/ard.2003.015925

Cooper, C., Adami, S., Stepan, J. J., Wiese, C., Wilson, K., Coutant, K., Dumont, E., & Reginster, J.-Y. (2004). A novel bisphosphonate dosing regimen: once-monthly oral ibandronate. Annals of the Rheumatic Diseases.

Gieschke, R., & Reginster, J.-Y. (2004). Clinical utility of a pharmacostatistical model for ibandronate in osteoporosis. Annals of the Rheumatic Diseases.

Reginster, J.-Y., Fischer, C. L., Beualieu, A., Malmstrom, K., Curtis, S. P., Miller, E. R., Bergman, G., Smolar, J., & Reicin, A. S. (2004). Etoricoxib demonstrates similar efficacy and improved gastrointestinal safety compared to naproxen in two 138-week randomized studies of osteoarthritis patients. Annals of the Rheumatic Diseases.

Reginster, J.-Y., & Richy, F. (2004). The OST risk tool performs consistently for identifying women at risk of osteoporosis across populations. Annals of the Rheumatic Diseases.

Ethgen, O., Bruyère, O., Richy, F., Dardennes, C., & Reginster, J.-Y. (May 2004). Health-related quality of life in total hip and total knee arthroplasty - A qualitative and systematic review of the literature. Journal of Bone and Joint Surgery. American Volume, 86 (5), 963-974. doi:10.2106/00004623-200405000-00012

Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., Rizzoli, R., Genant, H. K., & Reginster, J.-Y. (29 January 2004). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine, 350 (5), 459-468. doi:10.1056/NEJMoa022436

Ethgen, O., Gillain, D., Gillet, P., Gosset, C., Jousten, A., & Reginster, J.-Y. (2004). Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clinical and Experimental Research, 16 (5), 389-97. doi:10.1007/BF03324569

Ethgen, O., & Reginster, J.-Y. (January 2004). Degenerative musculoskeletal disease. Annals of the Rheumatic Diseases, 63 (1), 1-3. doi:10.1136/ard.2003.009613

Richy, F., Gourlay, M., Ross, P. D., Sen, S. S., Radican, L., De Ceulaer, F., Ben Sedrine, W., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (January 2004). Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM: Monthly Journal of the Association of Physicians, 97 (1), 39-46. doi:10.1093/qjmed/hch002

Christin-Maitre, S., Laveille, C., Collette, J., Brion, N., & Reginster, J.-Y. (01 November 2003). Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways. Journal of Clinical Endocrinology and Metabolism, 88 (11), 5405-5413. doi:10.1210/jc.2003-030094

Reginster, J.-Y., McClung, M., Coutant, K., Bonvoisin, B., Schimmer, R. C., & Delmas, P. D. (2003). Oral monthly ibandronate: rationale and clinical potential in postmenopausal osteoporosis. Annals of the Rheumatic Diseases.

Bruyère, O., Henrotin, Y., Honore, A., Rovati, L. C., Seidel, L., Dardenne, C.-B., & Reginster, J.-Y. (April 2003). Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clinical and Experimental Research, 15 (2), 136-41. doi:10.1007/BF03324491

Bruyère, O., Edwards, J., & Reginster, J.-Y. (2003). Fracture prevention in postmenopausal women. Clinical Evidence, 9, 1186-202.

Ethgen, O., Richy, F., Gosset, C., Hanssens, L., & Reginster, J.-Y. (2003). Prevention de la vulnerabilite de la personne agee: un defi demographique. Revue Médicale de Liège, 58 (4), 175-82.

Rabenda, V., Boniver, J., & Reginster, J.-Y. (2003). Numerus clausus en fin de troisieme candidature en medecine: mort annoncee d'une heresie? Revue Médicale de Liège, 58 (7-8, Jul-Aug), 508-14.

Reginster, J.-Y., Lecart, M.-P., Sarlet, N., & Halkin, V. (2003). Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003? Revue Médicale de Liège, 58 (4), 183-90.

Ethgen, O., & Reginster, J.-Y. (November 2002). L'evaluation de la qualite de vie dans les essais therapeutiques: un pas vers une approche holistique de la sante. Revue Médicale de Liège, 57 (11), 695-700.

Durez, P., Felsenberg, D., Stepan, J., Payer, J., Resch, H., Quail, D., Pavo, L., & Reginster, J.-Y. (June 2002). Reduction in vertebral fracture rates by a combination of monofluorophosphate and raloxifene in postmenopausal osteoporosis. Annals of the Rheumatic Diseases, 61 (Suppl.1).

Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., & Suryawanshi, S. (June 2002). Once weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Annals of the Rheumatic Diseases, 61 (Suppl.1).

Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., Deroisy, R., Machacek, S., Giacovelli, G., Gonzalez, C., & Reginster, J.-Y. (June 2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Annals of the Rheumatic Diseases, 61 (Suppl.1), 118.

Reginster, J.-Y., Bias, P., & Buchner, A. (June 2002). First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Annals of the Rheumatic Diseases, 61 (Suppl.1).

Reginster, J.-Y., Henrotin, Y., Bruyère, O., Gonzalez, C., Giacovelli, G., & Rovati, L. C. (June 2002). Joint space narrowing is poorly correlated with symptoms worsening in knee-osteoarthritis: results from the prospective follow-up of 106, placebo-treated patients for three years. Annals of the Rheumatic Diseases, 61 (Suppl.1), 121.

Reginster, J.-Y., Henrotin, Y., Deroisy, R., Giacovelli, G., Gonzalez, C., & Rovati, L. (June 2002). Correlation between mean and minimum joint space measurements in a long-term trial with glucosamine sulfate, an osteoarthritis modifying agent. Annals of the Rheumatic Diseases, 61 (Suppl.1).

Reginster, J.-Y., Rovati, L., Deroisy, R., Henrotin, Y., Gatterova, J., Machacek, S., Gonzalez, C., Giacovelli, G., & Pavelka, K. (June 2002). Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomised, placebo-controlled, double-blind, prospective 3-year trials. Annals of the Rheumatic Diseases, 61 (Suppl.1).

Johnell, O., Scheele, W. H., Lu, Y. L., Reginster, J.-Y., Need, A. G., & Seeman, E. (March 2002). Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism, 87 (3), 985-992. doi:10.1210/jcem.87.3.8325

Bruyère, O., Edwards, J., & Reginster, J.-Y. (2002). Fracture prevention in postmenopausal women. Clinical Evidence, 8, 1089-102.

Reginster, J.-Y., Paul, I., & Henrotin, Y. (July 2001). Comment positionner l'acéclofénac au sein de l'arsenal thérapeutique des pathologies ostéo-articulaires chroniques ? Revue Médicale de Liège, 56 (7), 484-8.

Henrotin, Y., Deby-Dupont, G., & Reginster, J.-Y. (June 2001). Les mediateurs biochimiques de l'inflammation. Revue Médicale de Liège, 56 (6), 433-42.

Reginster, J.-Y., & Henrotin, Y. (March 2001). Pharma clinics. Comment je traite.... L'arthrose. 2eme partie: Nouvelles perspectives therapeutiques. Revue Médicale de Liège, 56 (3), 135-9.

Reginster, J.-Y., & Henrotin, Y. (February 2001). Pharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique. Revue Médicale de Liège, 56 (2), 63-7.

Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Guillou, B., & Reginster, J.-Y. (2001). Long-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism. Tissue Engineering, 7 (5), 648.

Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Diacerein by its Metabolite Rhein, Down-Regulates Stromelysins and Nitric Oxide Productions and Up-Regulates Aggrecan Production by Human Chondrocytes in Alginate Beads. Tissue Engineering, 7 (5), 648.

Reginster, J.-Y., Henrotin, Y., Christiansen, C., Gamwell-Henriksen, E., Bruyère, O., Collette, J., & Christgau, S. (2001). Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcified Tissue International, 69 (3), 130-137. doi:10.1007/s002230020042

Sanchez, C., Deberg, M., Reginster, J.-Y., & Henrotin, Y. (2001). Long-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads. Annals of the Rheumatic Diseases, 60 (suppl1), 284.

Kaufman, J. M., Body, J. J., Boonen, S., Devogelaer, J. P., Raeman, F., Rozenberg, S., & REGINSTER, J.-Y. (2000). L'osteoporose involutive de la femme: strategie therapeutique. Un point de vue actualise du Belgian Bone Club. Revue Médicale de Liège, 55 (5), 443-8.

REGINSTER, J.-Y., & BETZ, R. (2000). Evidence-based medicine. Apport des etudes epidemiologiques. Revue Médicale de Liège, 55 (4), 211-5.

Reginster, J.-Y., Bruyère, O., Audan, M., Avouac, B., Body, J.-J., Bouvenot, G., Brandi, M.-L., Gennari, C., Kaufman, J.-M., Lemmel, E.-M., Vanhaelst, L., Weryha, G., & Devogelaer, J.-P. (2000). Do estrogens effectively prevent osteoporosis-related fractures? Calcified Tissue International, 67, 191-194. doi:10.1007/s002230001135

Reginster, J.-Y., Devogelaer, J. P., Kaufman, J. M., Appelboom, T., & Vanhaelst, L. (April 1999). L'ostéoporose d'involution chez la femme. Revue Médicale de Liège, 54 (4), 335-40.

Reginster, J.-Y., Devogelaer, J. P., Kaufman, J. M., Appelboom, T., & Vanhaelst, L. (March 1999). Comment j'explore ... l'ostéoporose: mesure de la masse osseuse et analyses biologiques. Revue Médicale de Liège, 54 (3), 184-8.

Reginster, J.-Y., Ben Sedrine, W., & Gosset, C. (1998). Les thérapeutiques à visée spécifiquement osseuse dans le traitement de l'ostéoporose postménopausique. Aspects pharmaco-économiques. Revue Médicale de Liège, 53 (5), 290-293.

Reginster, J.-Y., Frederick, I., Deroisy, R., Dewe, W., Taquet, A. N., Albert, A., Collette, J., Pirenne, H., Zheng, S. X., & Gosset, C. (1998). Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women. Osteoporosis International, 8 (4), 390-2. doi:10.1007/s001980050080

Reginster, J.-Y. (April 1997). Comment je traite ... L'ostéoporose sénile. Revue Médicale de Liège, 52 (4), 267-9.

Halkin, V., Francotte-Lempereur, N., Debrun, A., & Reginster, J.-Y. (March 1997). Le cas clinique du mois. Ostéoporose et beta-thalassémie. Revue Médicale de Liège, 52 (3), 138-41.

Reginster, J.-Y., Deroisy, R., Zegels, B., Denis, D., Reginster-Haneuse, G., Wilkin, P., Taziaux, P., Albert, A., & Boelen, C. (1997). Prévention de l'ostéoporose à Liège. Evaluation d'un essai de partenariat entre médecins généralistes et spécialistes universitaires (1). Revue Médicale de Liège, 52 (1), 31-36.

Reginster, J.-Y. (October 1996). Prévention de l'ostéoporose postménopausique: œstrogènes et thérapeutiques non hormonales. Revue Médicale de Liège, 51 (10), 649-53.

Reginster, J.-Y. (January 1996). Les bisphosphonates. Revue Médicale de Liège, 51 (1), 120-2.

Reginster, J.-Y. (January 1996). La calcitonine. Revue Médicale de Liège, 51 (1), 116-9.

Reginster, J.-Y. (June 1995). Calcium et squelette: base physiologique d'une prévention. Revue Médicale de Liège, 50 (6), 244-8.

Reginster, J.-Y. (01 May 1994). Calcitonine en prévention et traitement de l'ostéoporose. Revue Médicale de Liège, 49 (5), 253-9.

Reginster, J.-Y. (April 1994). La prévention de l'ostéoporose postménopausique en cas de contre-indications des œstrogènes. Revue Médicale de Liège, 49 (4), 194-8.

Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54

Wang, F.-C., de Marneffe, P., Reginster, J.-Y., Crielaard, J.-M., & Franchimont, P. (June 1991). Actualités en médecine de l'appareil locomoteur. Vascularité urticarienne: à propos d'un cas. Revue Médicale de Liège, 46 (6), 336-42.

Reginster, J.-Y., Damas, P., & Franchimont, P. (1984). L'anesthésie en pathologie ostéoarticulaire et ses problèmes spécifiques. Revue Médicale de Liège, 39 (1), 14-24.